Skip to main content
. Author manuscript; available in PMC: 2019 May 8.
Published in final edited form as: J Am Coll Cardiol. 2018 May 8;71(18):1999–2010. doi: 10.1016/j.jacc.2018.02.066

Figure 1. Trehalose treatment ameliorates chronic ischemic remodeling.

Figure 1

A–F. Mice with and without LAD ligation received placebo (CT), sucrose (SUC) or trehalose (TRE). After 4 weeks, they were subjected to echocardiographic analysis to assess left ventricular end-diastolic diameter (LVEDD, B) and fractional shortening (FS, C). N=9 in placebo sham group; N=9 in sucrose sham group; N=10 in trehalose sham group; N=19 in placebo MI group; N=14 in sucrose MI group; N=21 in trehalose MI group. Mice were also subjected to hemodynamic analysis in order to assess the slope of the end-systolic pressure volume relationship (ESPVR), the relaxation constant Tau (D), the left ventricular stiffness (E) and the left ventricular end-diastolic pressure (LVEDP, F). N=7 in each sham group; N=18 in placebo MI group; N=14 in sucrose MI group; N=19 in trehalose MI group. *p<0.05; **p<0.01; ***p<0.001.